Clinical trial
A Study of SGN-CEACAM5C in Adults With Advanced Solid Tumors
NCT06131840
Study timeline
Study start (actual)2023-11-20Date precision: day
Registry last updated2026-07-22
Observed by CureCurrent2026-10-07
Recorded dates are source observations, not predictions. Missing milestones are not estimated.
Conditions
Colorectal Neoplasmsunresolved
Carcinoma, Non-Small-Cell Lungunresolved
Stomach Neoplasmsunresolved
Pancreatic Ductal Adenocarcinomaunresolved
Gastroesophageal Junction Adenocarcinomaunresolved
Small Cell Lung Carcinomaunresolved
Interventions
PF-08046050DRUG
bevacizumabDRUG · verified · RxNorm: bevacizumab
OxaliplatinDRUG · verified · RxNorm: oxaliplatin
Leucovorin (LV)DRUG
Sponsors & collaborators
Seagen, a wholly owned subsidiary of Pfizerlead sponsor
Sanoficollaborator
Mapped research locations
LondonUnited Kingdom4TorontoOntario, Canada2NashvilleTennessee, United States2OrlandoFlorida, United States2AuroraColorado, United States2RochesterMinnesota, United States2DuarteCalifornia, United States2EdinburghUnited Kingdom2HoustonTexas, United States1BostonMassachusetts, United States1BaltimoreMaryland, United States1San AntonioTexas, United States1
Registry source
Open the source record to verify current eligibility, contacts, locations and registry updates.
Open NCT06131840 on ClinicalTrials.gov ↗Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.